Managing high-risk CLL during transition to a new treatment era: Stem cell transplantation or novel agents?

  • Dreger P
  • Schetelig J
  • Andersen N
 et al. 
  • 78


    Mendeley users who have this article in their library.
  • 105


    Citations of this article.


Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Johannes Schetelig

  • Niels Andersen

  • Paolo Corradini

  • Michel Van Gelder

  • John Gribben

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free